Investigating Toxicities With Lenvatinib Plus Paclitaxel in Ovarian and Endometrial Cancers

May 17, 2019

Floor J. Backes, MD, discusses the side effects associated with the combination lenvatinib plus paclitaxel in patients with recurrent endometrial and platinum-resistant epithelial ovarian cancer.

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses the side effects associated withthe combination lenvatinib (Lenvima) plus paclitaxel in patients with recurrent endometrial and platinum-resistant epithelial ovarian cancer.

The toxicities were typical to that of other chemotherapy agents, says Backes. This includes cytopenia, anemia, leukopenia, and some thrombocytopenia. It was mostly the white and red cells that were affected.

Related Content